Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Vaccines
BioNTech plans mRNA vaccine plant in Africa
by Michael McCoy
October 30, 2021
| A version of this story appeared in
Volume 99, Issue 40
BioNTech has followed Moderna in announcing plans to build a plant in Africa for messenger RNA (mRNA)–based vaccines for COVID-19 and other diseases. BioNTech says it will begin construction in mid-2022, though it has not specified a location. Amid criticism that it is neglecting the developing world, Moderna said in October that it will spend $500 million on an mRNA facility at an unspecified location in Africa. On Oct. 26, Moderna said it will make up to 110 million doses of its COVID-19 vaccine available to the African Union.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter